Isatori 10-Q 11 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 11, 2014
Document And Entity Information	'	'
Entity Registrant Name	'iSatori, Inc.	'
Entity Central Index Key	'0000741114	'
Document Type	'10-Q	'
Document Period End Date	30-Jun-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'No	'
Is Entity's Reporting Status Current?	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	12,892,754
Document Fiscal Period Focus	'Q2	'
Document Fiscal Year Focus	'2014	'

Condensed_Balance_Sheets_Unaud

Condensed Balance Sheets (Unaudited) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$1,717,916	$822,876
Accounts receivables	'	'
Trade, net of allowance for doubtful accounts	2,148,148	2,398,178
Inventories	2,246,804	1,985,764
Income tax receivable	0	102,452
Note receivables - current portion	7,357	11,013
Assets held for sale	35,185	108,228
Deferred tax asset, net	47,918	53,081
Prepaid expenses	212,153	222,466
Total current assets	6,415,481	5,704,058
Property and equipment, net of accumulated depreciation	157,046	173,636
Note receivable - net of current portion	81,714	81,714
Other assets:	'	'
Deferred tax asset, net	143,956	147,941
Deposits and other assets	33,858	61,167
Total other assets	177,814	209,108
Total assets	6,832,055	6,168,516
Current liabilities	'	'
Trade accounts payable	1,354,883	1,248,490
Accrued expenses	315,743	187,608
Deferred revenues	214,977	292,215
Line of credit, less debt discount	1,220,519	1,220,655
Notes payable	18,117	20,464
Total current liabilities	3,124,239	2,969,432
Long-term liabilities	'	'
Derivative liability	279,013	471,015
Commitments and contingencies	'	'
Stockholders' Equity	'	'
Convertible preferred stock	225	225
Common stock	128,872	128,797
Additional paid-in-capital	4,759,857	4,731,535
Accumulated deficit	-1,460,151	-2,132,488
Total stockholders' equity	3,428,803	2,728,069
Total liabilities and stockholders' equity	$6,832,055	$6,168,516

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]	'	'
Convertible preferred stock, par value per share in dollars	$0.01	$0.01
Convertible preferred stock, shares authorized	750,000	750,000
Convertible preferred stock, shares issued	22,500	22,500
Convertible preferred stock, shares outstanding	22,500	22,500
Convertible preferred stock, liquidation value	$450,000	$450,000
Common stock, par value in dollars	$0.01	$0.01
Common stock, shares authorized	56,250,000	56,250,000
Common stock, shares issued	12,887,151	12,879,651
Common stock, shares outstanding	12,887,151	12,879,651

Condensed_Statements_of_Operat

Condensed Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenue:	'	'	'	'
Product revenue (net of returns and discounts)	$2,877,496	$2,240,574	$6,096,740	$4,444,430
Royalty revenue	30,501	33,813	63,127	66,524
Other revenue	10,370	5,541	19,767	25,341
Total revenue	2,918,367	2,279,928	6,179,634	4,536,295
Cost of sales	1,306,245	957,452	2,550,043	2,002,566
Gross profit	1,612,122	1,322,476	3,629,591	2,533,729
Operating Expenses:	'	'	'	'
Selling and marketing	477,413	295,023	1,260,101	611,199
Salaries and labor related expenses	600,968	511,006	1,248,381	1,045,334
Administration	299,775	452,711	513,753	869,158
Depreciation and amortization	20,015	27,339	39,144	52,355
Total operating expenses	1,398,171	1,286,079	3,061,379	2,578,046
Income (loss) from operations	213,951	36,397	568,212	-44,317
Other income (expense)	204,642	-77,518	234,842	-201,877
Financing expense	9,476	8,572	30,827	55,333
Interest expense	9,636	11,433	20,685	12,585
Income (loss) before income taxes	399,481	-61,126	751,542	-314,112
Income tax benefit (expense)	-63,382	194,348	-79,205	184,214
Net income (loss)	$336,099	$133,222	$672,337	($129,898)
Net income/(loss) per common share, Basic	$0.03	$0.01	$0.05	($0.01)
Net income/(loss) per common share, Diluted	$0.02	$0.01	$0.05	($0.01)
Weighted average shares outstanding, Basic	12,886,401	12,686,928	12,883,026	12,654,842
Weighted average shares outstanding, Diluted	13,686,754	13,738,886	13,714,797	12,654,842

Condensed_Statements_of_Cash_F

Condensed Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:	'	'
Net income/(loss)	$672,337	($129,898)
Adjustments to reconcile net income/(loss) to net cash provided by (used in) operating activities:	'	'
Depreciation and amortization	39,144	52,355
Amortization of debt discount	0	3,750
Share based compensation expense	28,397	127,364
Change in value of assets held for sale	-14,800	-59,751
Change in fair value of derivative instruments	-192,002	112,899
Provision for (benefit from) deferred income taxes	66,152	-197,729
Change in assets and liabilities:	'	'
Accounts receivable	250,030	-104,568
Income tax receivable	45,448	0
Notes receivable	3,656	237
Inventory	-261,040	-400,127
Prepaid expenses	10,313	-140,752
Deposits and other assets	20,904	-21,559
Trade accounts payable	106,393	153,215
Accrued expenses	128,135	44,638
Deferred revenues	-77,238	396,451
Net cash provided by (used in) operating activities	825,829	-163,475
Cash flows from investing activities:	'	'
Purchase of property and equipment	-16,149	-104,969
Proceeds from the sale of assets held for sale	87,843	26,919
Sale of investments	0	965,886
Net cash provided by investing activities	71,694	887,836
Cash flows from financing activities:	'	'
Proceeds from notes payable	0	25,101
Payment of notes payable	-2,347	-2,341
Payment of line of credit	-136	0
Proceeds from exercise of warrants	0	334
Net cash (used in) provided by financing activities	-2,483	23,094
Net increase in cash	895,040	747,455
Cash and cash equivalents, beginning of year	822,876	1,655,453
Cash and cash equivalents, end of year	1,717,916	2,402,908
Supplemental Disclosure of Cash Flow Information	'	'
Cash paid for interest	26,670	24,281
Cash paid for taxes	$6,700	$6,863

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	Note 1 - Summary of Significant Accounting Policies
	Organization and Nature of Business, and Basis of Presentation
	iSatori, Inc (the “Company”) was incorporated under the laws of the state of Delaware on June 29, 2012. The trading symbol of the Company on OTCBB is “IFIT”.
	The Company is engaged in researching, designing, developing, contracting for the manufacture, marketing, selling and distributing of various branded nutritional and dietary supplement products for the general nutrition market. The “general nutrition market” may include such activities as body-building, weight-training, physique enhancement (increase of lean body mass and decrease in fat mass) and enhanced athletic performance through increased strength and/or endurance and proper nutrition.
	The Company does engage from time to time in funding of clinical studies with the objective of discovering and/or validating claims of new, efficacious products for the Company’s relevant market as well as providing necessary and appropriate substantiation for any claims which the Company may use in its marketing and advertising. The Company markets products which are under its control and which are in some way proprietary to the Company. Some of the Company’s products are the subject of patents, service marks and or trademarks owned by the Company.
	Unaudited Interim Financial Information
	The accompanying interim condensed financial statements have been prepared in accordance with our accounting practices described in our audited financial statements for the year ended December 31, 2013, and are unaudited. These unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December 31, 2013. The accompanying interim condensed financial statements are presented in accordance with the rules and regulations of the Securities and Exchange Commission and, accordingly, do not include all the disclosures required by generally accepted accounting principles in the United States (“U.S. GAAP”) with respect to annual financial statements. In the opinion of management, all adjustments, consisting of normal recurring accruals that are considered necessary for a fair presentation of the interim condensed financial information, have been included. However, operating results for the periods presented are not necessarily indicative of the results that may be expected for a full year.
	Financial Instruments
	The Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Accordingly, cash and cash equivalents consist of petty cash, checking accounts and money market funds.
	Fair Value Measurements
	ASC 820-10 establishes a framework for measuring the fair value of assets and liabilities and requires additional disclosure about fair value measurements. ASC 820-10 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in the principal (or most advantageous market) for the asset or liability in an orderly transaction between market participants at the measurement date.
	The Company has a number of financial instruments, including cash, cash equivalents. receivables, inventory, payables and debt obligations. The carrying amount of cash and cash equivalents, receivables, accounts payable, accrued expenses and notes payable approximates their fair value because of the short maturity of these instruments. As further described in Note 7, the Company has issued warrants which are measured at fair value on a recurring basis and result in a long-term derivative liability on the balance sheet. The actual and estimated fair values, respectively, of the Company’s financial instruments are as follows:
		30-Jun-14					31-Dec-13
		Carrying		Fair Value			Carrying		Fair Value
		Amount					Amount
	Cash and cash equivalents	$	1,717,916	$	1,717,916		$	822,876	$	822,876
	Receivables	$	2,148,148	$	2,148,148		$	2,398,178	$	2,398,178
	Accounts Payable	$	1,354,883	$	1,354,883		$	1,248,490	$	1,248,490
	Derivative Liability	$	279,013	$	279,013		$	471,015	$	471,015
	Trade Receivables and Credit Policy
	Trade receivables are uncollateralized customer obligations due under normal trade terms requiring payment generally within 10-60 days from the invoice date. Accounts are considered delinquent when outstanding for more than 7 days past due date. The Company does not have a policy of accruing interest on past due accounts. Payments on trade receivables are applied as instructed per the customer, or to the earliest unpaid invoices. The allowance for doubtful accounts represents an estimate of amounts considered uncollectible and is determined based on management’s historical collection experience, adverse situations that may affect the customer’s ability to repay, and prevailing economic conditions. Specific accounts deemed uncollectible are written off periodically with subsequent receipts on previously written off accounts credited to bad debt expense. The allowance for doubtful accounts is $0 for each of the periods ended June 30, 2014 and December 31, 2013. Receivables at each of the below respective periods consisted of the following:
		June 30,		December 31,
		2014		2013
	Trade Receivables	$	2,085,330	$	2,323,522
	Other	$	62,817	$	74,656
	Allowance for doubtful accounts	$	0	$	0
	Totals	$	2,148,147	$	2,398,178
	In addition, the Company has recorded an allowance for customer returns in the amount of approximately $85,000 and $70,000 at June 30, 2014 and December 31, 2013, respectively, in accrued expenses.
	Inventory Valuation
	Inventories of nutritional and dietary supplements are stated at lower of cost or market on a first-in, first-out (FIFO) basis as noted below:
		June 30,		December 31,
		2014		2013
	Labels and packaging	$	182,397	$	120,057
	Raw materials	$	79,836	$	207,320
	Finished goods	$	1,984,571	$	1,658,387
	Totals	$	2,246,804	$	1,985,764
	Note Receivable
	The predecessor company disposed of a dormant product line of vitamins in December 2010. As part of the consideration in this divestiture, the Company received from the purchaser of this product line an unsecured note in the amount of $170,000. The original note was due to be repaid on or before March 2014, where interest accrued principally at an annual rate of 5%, based upon the initial $170,000 principal and was payable monthly. As of March 31, 2013, the note was novated and a new promissory note was issued to reflect a modification in the payment terms, which includes no interest. The total note receivable balance at June 30, 2014 was $89,071, and is due to be repaid in monthly increments through May 1, 2017.
	Revenue Recognition
	The Company operates predominantly as a distributor of its dietary supplement products through traditional large retailers and electronic intermediaries. Revenue from product sales is recognized upon transfer of title to the Company’s product to its customers. Net sales represent product sales less actual returns, allowances, discounts, and promotions. Sales to direct customers have an unconditional money back guarantee for thirty to sixty days after the date of purchase. Sales to several of the retail customers carry a “Sale or Return” Purchase agreement per contract, where if minimum sales thresholds are not met within required timeframe, the inventory will be returned to the Company for full credit. Other retail customers receive a percentage discount from invoice to cover any customer returns or damages they may incur. Returns, allowances and discounts, and promotions were $849,356 and $293,498 for the three month period ended June 30, 2014 and 2013, respectively. Returns, allowances and discounts, and promotions were $1,360,091 and $1,008,528 for the six month period ended June 30, 2014 and 2013, respectively.
	In addition, the Company provides allowances for sales returns based upon estimated and known returns. Product returns are recorded as a reduction of net revenues and as a reduction of the accounts receivable balance.
	The Company receives other revenues which include but are not limited to shipping and handling charges billed to customers.
	The Company has recorded $214,977 as of June 30, 2014 in deferred revenue as a liability pertaining to inventory sold under consignment terms, even though it has already been paid for by the customer.
	Cost of Sales
	The Company purchases its products directly from third party manufacturers. The Company’s cost of sales include product costs, including any associated materials used in production, cost of warehousing and distribution. Included in the cost of sales are transit freight and shipping and handling costs that are incurred by the Company.
	Income Taxes
	The Company utilizes the asset and liability method of accounting for income taxes. Under this asset and liability method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities, and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. See Note 4, “Income Taxes”.
	Since 2012 was the Company’s initial tax year, there are no prior federal or state tax returns subject to examination. Accordingly, the only taxable periods subject to examination by federal and state taxing authorities are the periods ended December 31, 2013 and 2012. Federal and state tax returns for the Company prior to the short form merger are open for the period ended December 31, 2011.
	Leases
	The Company leases its headquarters facility, comprising approximately 10,044 square feet, in Golden (metropolitan Denver), Colorado. The total rent expense for each of the three month periods ended June 30, 2014 and 2013, was $20,716. The total rent expense for each of the six month periods ended June 30, 2014 and 2013, was $41,432. The lease term expires January 31, 2017 and requires equal monthly payments over the remaining term. Future payments under the lease total $214,063. The Company also leases miscellaneous office and warehouse equipment. In most cases, management expects that in the normal course of business these leases will be renewed or replaced by other leases as applicable.
	Marketing
	The Company expenses all production costs related to advertising costs as they are incurred, including print, digital, and television when the advertisement has been broadcast or otherwise finished and or distributed. The Company records website costs related to its direct-to-consumer advertisements in accordance with FASB ASC 340-20 “Capitalized Advertising Costs”. In accordance with FASB ASC 340-20, direct response advertising costs incurred should be reported as assets and should be amortized over the estimated period of the benefits, based on the proportion of current period revenue from the advertisements to probable future revenue. As of June 30, 2014 and December 31, 2013, the Company had deferred $0 and $7,651 respectively, related to such advertising costs. This amount was included in Deposits and other assets and amortized over a one year period, the estimated time frame to which the existing commercial was used. For the three month period ended June 30, 2014 and 2013, marketing expenses totaled $314,696 and $178,720, respectively. For the six month period ended June 30, 2014 and 2013, marketing expenses totaled $942,119 and $324,930, respectively.
	Research and Development Costs
	Research and development costs, which includes the funding of clinical research studies, are expensed when incurred. Research and development costs of $4,481 and $28,701 for the three month period ended June 30, 2014 and 2013, respectively, are included in selling and marketing expense. Research and development costs of $10,905 and $88,514 for the six month period ended June 30, 2014 and 2013, respectively, are included in selling and marketing expense.
	Distribution, Shipping and Handling Costs
	Shipping costs on purchases and shipping and handling fees related to sales charged to customers are both included in cost of sales. As mentioned in Revenue Recognition, shipping and handling revenue billed customers are reflected in other revenues.
	Concentration of Credit Risk
	Financial instruments that potentially subject the Company to concentration of credit risk consist principally of trade accounts receivables. Concentrations of credit with respect to trade receivables are limited due to the large number of customers comprising the Company’s customer bases and their dispersion across different geographic locations.
	The Company maintains cash balances at one financial institution located in Colorado and one in California. Accounts at these institutions are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000 per account. At times during the year, the Company’s bank balances have exceeded the FDIC limit. Management believes the risk of loss at such institutions to be minimal.
	During the six month period ended June 30, 2014, sales to three customers made up 66% of total product revenue, with each customer representing greater than 10% of product revenue on an individual basis. These customers’ combined accounts receivable balances were 80% of total accounts receivable at June 30, 2014. During the six month period ended June 30, 2013, sales to three customers made up 57% of total product revenue, with each customer representing greater than 10% of product revenue on an individual basis. These customers’ combined accounts receivable balances were 56% of total accounts receivable as of June 30, 2013. During the six month period ended June 30, 2014, purchases from three vendors made up 63% of total inventory purchases. These vendors’ combined accounts payable balances were 48% of total accounts payable as of June 30, 2014. During the six month period ended June 30, 2013, purchases from two vendors made up 78% of total inventory purchases. These vendors’ combined accounts payable balances were 68% of total accounts payable as of June 30, 2013.
	Use of Estimates
	The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include but are not limited to the fair value determination of derivative instruments, the valuation allowance with respect to estimated utilization of net operating losses, estimated allowances for sales returns and collectability of trade receivables.
	Earnings (Loss) Per Share
Net earnings (loss) per share is computed by dividing net income (loss) less preferred dividends for the period by the weighted average number of shares of common stock outstanding during each period. Diluted earnings (loss) per share is computed by dividing net income (loss) less preferred dividends for the period by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during each period.
Since the Company reflected a net loss for the six month period ended June 30 2013, the effect of considering any common stock equivalents, if exercisable, would have been anti-dilutive.
The Company has the following common stock equivalents as of June 30, 2014 and 2013:
		Three Months Ended			Six Months Ended
		2014	2013		2014		2013
Basic weighted average common shares outstanding		12,866,401	12,686,928		12,883,026		12,645,842
Stock options (exercise price – $0.573-$2.50/share)		382,258	614,488		413,280		581,145
Warrants (exercise price – $0.001-$2.25/share)		418,095	437,450		418,491		431,648
Total common stock equivalents		13,686,754	13,738,866		13,714,797		13,658,635

Contingencies

Contingencies	6 Months Ended
	Jun. 30, 2014
Loss Contingency [Abstract]	'
Contingencies	'
	Note 2 - Contingencies
	In accordance with the standards on contingencies, the Company accrues a loss contingency if it is probable and can reasonably be estimated or a liability has been incurred at the date of the financial statements. If both of these conditions are not met, or if an exposure to loss exists in excess of the amount accrued, disclosure of the contingency shall be made when there is at least a reasonable possibility that a loss or an additional loss may have been incurred. The Company is exposed to legal claims encountered in the normal course of business. See Note 3, “Litigation”. Management believes that the ultimate resolution of these matters will not have a material adverse effect on the operating results or the financial position of the Company.

Litigation

Litigation	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Litigation	'
	Note 3 - Litigation
	The Company is engaged in various legal actions, claims and proceedings arising in the normal course of business, including claims related to breach of contracts, product liabilities and intellectual property matters resulting from the Company’s business activities. As with most actions such as these, an estimation of any possible and/or ultimate liability cannot always be determined. The following summaries highlight the current status of certain material commercial litigation in which the Company is involved.
	On May 17, 2013 and on January 31, 2014, the Company received demand letters from the Environmental Research Corporation, “ERC” requesting substantiation of compliance with the State of California’s Proposition 65 regulations for ten of its products. The Company is in communication with ERC and has begun discussions regarding claims as outlined in the demand letters. The Company believes that there is a reasonable possibility, as defined by FASB ASC 450-20, of an unfavorable outcome. However, the range of any possible loss cannot be reasonably estimated as of the date of the financial statements.
	On March 24, 2014, the Company received a summons in a civil action filed by Wise Sports Nutrition, LLC claiming alleged trademark infringement for iSatori’s Garcinia Trim product. Company counsel has made contact with the plaintiff’s attorney and filed a response to the alleged trademark infringement with the Company’s counterclaims. The Company believes the counterclaims have strong merit and are pursuing their defense. Both parties are now preparing responses to be presented to the court. The Company believes that it is too early in the proceedings to make a determination of either a favorable or unfavorable outcome. Therefore, no range of any possible gain or loss can be reasonably estimated as of the date of the financial statements.

Income_Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Note 4 - Income Taxes
	For the three months ended June 30, 2014, the Company recognized income tax expense of $63,382, and for the three months ended June 30, 2013, the Company recognized an income tax benefit of $194,348.
	For the six months ended June 30, 2014, the Company recognized income tax expense of $79,205, and for the six months ended June 30, 2013, the Company recognized an income tax benefit of $184,214.
	The difference between the six months ended June 30, 2014 effective rate of 8.96% and the Federal statutory rate of 35.0% is primarily due to state income taxes (net of federal benefit), change in the valuation allowance, and an adjustment to the income tax receivable.
	At June 30, 2014 management believes there are no uncertain tax positions.

Stockholders_Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Stockholders' Equity	'
	Note 5- Stockholders’ Equity
	At June 30, 2014, there were 12,887,151 shares of common stock, par value $.01 per share, outstanding for the Company.
	The Company issued warrants, now totaling 420,549 shares, to purchase 3% of fully diluted shares of the common stock of the Company to Breakwater Structured Growth Opportunity Fund, L.P., with an imputed exercise price equal to approximately one-hundredth of a dollar in connection with a $1.025 million subordinated mezzanine loan arrangement. These warrants are fully vested and expire on June 15, 2016. The Company used a lattice model in developing a fair value for the Breakwater warrant obligation at June 30, 2014, using a quoted stock value of $0.68 per share, which represents a discount of 50% from the closing stock price. This reduction was based on the application of a discount for lack of liquidity. Other assumptions used in the above valuations include (a) risk-free interest rate of .47% based on duration, (b) weighted average expected term years of 2.04 (c) weighted average expected stock volatility of 38.18% (e) expected dividends of 0%, (f) stock price movements ranging from 1.05437284 to 0.94843111 and (g) risk neutral probabilities ranging from 0.4876197 to 0.5123803.
	This valuation resulted in income of $191,279 in the Statement of Operations for the three month period ended June 30, 2014, and income of $192,002 in the Statement of Operations for the six month period ended June 30, 2014. For the three month period ended June 30, 2013, the valuation resulted in income of $58,837, and expense of $100,968 in the Statement of Operations for the six month period ended June 30, 2014.
	On April 1, 2014, the Company issued 7,500 shares of its $.01 par value common stock to a business development consultant. The Company considered the fair value of the shares issued to be the most reliable measure of compensation to the consultant. At the time of the issuance, the Company’s stock price was $2.17 per share, and therefore the issuance resulted in $16,275 of share based compensation expense for the three and six months ended June 30, 2014.
	2012 Performance Incentive Plan
	On September 27, 2012, the Company’s Board of Directors approved the 2012 Performance Incentive Plan (the Plan”). The Plan allows the Company to promote the success of the Corporation and to increase stockholder value by providing an additional means through the grant of awards to attract, motivate, retain and reward selected employees and other eligible persons. Any stock option granted in the form of an incentive stock option will be intended to comply with the requirements of Section 422 of the Code. Only stock options granted to employees qualify for incentive stock option treatment. A stock option may be exercised in whole or in installments, which may be cumulative. Shares of common stock purchased upon the exercise of a stock option must be paid for in full at the time of the exercise in cash or such other consideration determined by the compensation committee. Payment may include tendering shares of common stock or surrendering of a stock award, or a combination of methods.
	The Plan is administered by the Plan Administrator, being the Board or one or more committees appointed by the Board or another committee (within its delegated authority) to administer all or certain aspects of this Plan. The Administrator has full and exclusive power within the limitations set forth in the Plan to make all decisions and determinations regarding the selection of participants and the granting of awards; establishing the terms and conditions relating to each award; adopting rules, regulations and guidelines; and interpreting the Plan.
	On January 2, 2014, the Company issued options to purchase 10,000 shares of the Company’s common stock to an employee with an exercise price of $2.50 per share and which contain three year vesting schedules of 1/3 each year through October 2016. These options are due to expire on October 15, 2023.
	On February 10, 2014, the Company issued options to purchase 6,000 shares of the Company’s common stock to an employee with an exercise price of $2.22 per share and which contain three year vesting schedules of 1/3 each year through February 2017. These options are due to expire on February 10, 2024.
	The Company, in developing a fair value for the employee options used a current stock price of $1.11-1.25, which represents a discount of 50% from the quoted stock price for lack of marketability. Other assumptions used in the above valuations include (a) risk-free interest rate of 2.13-2.41% based on duration, (b) weighted average expected terms ranging from 6.08 to 6.33 years; (c) weighted average expected stock volatility of 35.22 % and (e) expected dividends of 0%.
	The Company has recorded share based compensation expense due to issuances under the Plan totaling $6,017 for the three months ended June 30, 2014, and has recorded share based compensation expense due to issuances under the Plan totaling $12,122 for the six months ended June 30, 2014.

Revolving_Line_of_Credit_and_R

Revolving Line of Credit and Related Interest	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Revolving Line of Credit and Related Interest	'
	Note 6- Revolving Line of Credit and Related Interest
	The Company entered into a Credit Agreement with Colorado Business Bank West of Denver, Colorado on July 16, 2012, which was renewed effective October 16, 2013. Borrowings under this agreement are used to provide ongoing working capital and for other general corporate purposes of the Company.
	The agreement provides a revolving commitment to the Company of $1,500,000. Amounts outstanding under the agreement are reflected in a promissory note with a principal balance of $1,500,000 and maturity date of November 16, 2014 (the “Promissory Note”). The principal balance on the Promissory Note will bear interest at the one month USD LIBOR rate measured not more often than once per month (the “Index”). Interest on any unpaid balance under the promissory note will bear interest at the Index plus 3.75% with a minimum interest rate of 4.00% per annum.
	The outstanding balance on the revolving line of credit as of June 30, 2014 and December 31, 2013 was $1,220,519 and $1,220,655, respectively.

Fair_Value_Measurements_and_Di

Fair Value Measurements and Disclosures	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements and Disclosures	'
	Note 7 - Fair Value Measurements and Disclosures
	The Company follows ASC 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for using fair value to measure assets and liabilities, and expands disclosures about fair value measurements. The statement establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions of what market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the reliability of the inputs as follows:
	Level 1: Quoted prices are available in active markets for identical assets or liabilities.
	Level 2: Quoted prices in active markets for similar assets and liabilities that are observable for the asset or liability; or
	Level 3: Unobservable pricing inputs that are generally less observable from objective sources, such as discounted cash flow models or valuations.
	ASC 820 requires financial assets and liabilities to be classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.
	For the purposes of marketable securities where there is an active market, the Company uses the quoted prices available for the identical asset or liability. As of June 30, 2014, the Company had $35,185 assets held for sale valued using the Level 1 mark-to-market approach. As of December 31, 2013, the Company had $108,228 assets held for sale valued using the Level 1 mark-to-market approach.
	The inputs used in the fair value measurements categorized within Level 3 include the stock price at the valuation date, the exercise price of the warrant, the expected period of time the warrant will be outstanding, the annual volatility of the underlying stock price, the annual yield rate of quarterly dividends, and the risk free rate of interest relevant to the expected time period the warrant will be outstanding.
	The following table represents the Company’s warrant derivative liabilities that were accounted for at fair value on a recurring basis by level within the fair value hierarchy:
		30-Jun-14						31-Dec-13
		Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
	Balance	$	35,185	$	0	$	279,013	$	108,228	$	0	$	471,015
	Beginning of Period		108,228		-		471,015		29,338		-		701,852
	Deletions		-87,843		-		-		-36,103		-		-87,755
	Revisions		14,800		-		-192,002		114,993		-		-143,082
	End of Period	$	35,185	$	0	$	279,013	$	108,228	$	0	$	471,015

Accounting_Policies_Policies

Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Organization and Nature of Business	'
	Organization and Nature of Business, and Basis of Presentation
	iSatori, Inc (the “Company”) was incorporated under the laws of the state of Delaware on June 29, 2012. The trading symbol of the Company on OTCBB is “IFIT”.
	The Company is engaged in researching, designing, developing, contracting for the manufacture, marketing, selling and distributing of various branded nutritional and dietary supplement products for the general nutrition market. The “general nutrition market” may include such activities as body-building, weight-training, physique enhancement (increase of lean body mass and decrease in fat mass) and enhanced athletic performance through increased strength and/or endurance and proper nutrition.
	The Company does engage from time to time in funding of clinical studies with the objective of discovering and/or validating claims of new, efficacious products for the Company’s relevant market as well as providing necessary and appropriate substantiation for any claims which the Company may use in its marketing and advertising. The Company markets products which are under its control and which are in some way proprietary to the Company. Some of the Company’s products are the subject of patents, service marks and or trademarks owned by the Company.
	Unaudited Interim Financial Information
	The accompanying interim condensed financial statements have been prepared in accordance with our accounting practices described in our audited financial statements for the year ended December 31, 2013, and are unaudited. These unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December 31, 2013. The accompanying interim condensed financial statements are presented in accordance with the rules and regulations of the Securities and Exchange Commission and, accordingly, do not include all the disclosures required by generally accepted accounting principles in the United States (“U.S. GAAP”) with respect to annual financial statements. In the opinion of management, all adjustments, consisting of normal recurring accruals that are considered necessary for a fair presentation of the interim condensed financial information, have been included. However, operating results for the periods presented are not necessarily indicative of the results that may be expected for a full year.
Financial Instruments	'
	Financial Instruments
	The Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Accordingly, cash and cash equivalents consist of petty cash, checking accounts and money market funds.
Fair Value Measurements	'
	Fair Value Measurements
	ASC 820-10 establishes a framework for measuring the fair value of assets and liabilities and requires additional disclosure about fair value measurements. ASC 820-10 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in the principal (or most advantageous market) for the asset or liability in an orderly transaction between market participants at the measurement date.
	The Company has a number of financial instruments, including cash, cash equivalents. receivables, inventory, payables and debt obligations. The carrying amount of cash and cash equivalents, receivables, accounts payable, accrued expenses and notes payable approximates their fair value because of the short maturity of these instruments. The Company has issued warrants which are measured at fair value on a recurring basis and result in a long-term derivative liability on the balance sheet.
Trade Receivables and Credit Policy	'
	Trade Receivables and Credit Policy
	Trade receivables are uncollateralized customer obligations due under normal trade terms requiring payment generally within 10-60 days from the invoice date. Accounts are considered delinquent when outstanding for more than 7 days past due date. The Company does not have a policy of accruing interest on past due accounts. Payments on trade receivables are applied as instructed per the customer, or to the earliest unpaid invoices. The allowance for doubtful accounts represents an estimate of amounts considered uncollectible and is determined based on management’s historical collection experience, adverse situations that may affect the customer’s ability to repay, and prevailing economic conditions. Specific accounts deemed uncollectible are written off periodically with subsequent receipts on previously written off accounts credited to bad debt expense.
Inventory Valuation	'
	Inventory Valuation
	Inventories of nutritional and dietary supplements are stated at lower of cost or market on a first-in, first-out (FIFO) basis.
Revenue Recognition	'
	Revenue Recognition
	The Company operates predominantly as a distributor of its dietary supplement products through traditional large retailers and electronic intermediaries. Revenue from product sales is recognized upon transfer of title to the Company’s product to its customers. Net sales represent product sales less actual returns, allowances, discounts, and promotions. Sales to direct customers have an unconditional money back guarantee for thirty to sixty days after the date of purchase. Sales to several of the retail customers carry a “Sale or Return” Purchase agreement per contract, where if minimum sales thresholds are not met within required timeframe, the inventory will be returned to the Company for full credit. Other retail customers receive a percentage discount from invoice to cover any customer returns or damages they may incur.
	In addition, the Company provides allowances for sales returns based upon estimated and known returns. Product returns are recorded as a reduction of net revenues and as a reduction of the accounts receivable balance.
	The Company receives other revenues which include but are not limited to shipping and handling charges billed to customers.
Cost of Sales	'
	Cost of Sales
	The Company purchases its products directly from third party manufacturers. The Company’s cost of sales include product costs, including any associated materials used in production, cost of warehousing and distribution. Included in the cost of sales are transit freight and shipping and handling costs that are incurred by the Company.
Income Taxes	'
	Income Taxes
	The Company utilizes the asset and liability method of accounting for income taxes. Under this asset and liability method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities, and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled.
Marketing	'
	Marketing
	The Company expenses all production costs related to advertising costs as they are incurred, including print, digital, and television when the advertisement has been broadcast or otherwise finished and or distributed. The Company records website costs related to its direct-to-consumer advertisements in accordance with FASB ASC 340-20 “Capitalized Advertising Costs”. In accordance with FASB ASC 340-20, direct response advertising costs incurred should be reported as assets and should be amortized over the estimated period of the benefits, based on the proportion of current period revenue from the advertisements to probable future revenue.
Research and Development Costs	'
	Research and Development Costs
	Research and development costs, which includes the funding of clinical research studies, are expensed when incurred and are included in selling and marketing expense.
Distribution, Shipping and Handling Costs	'
	Distribution, Shipping and Handling Costs
	Shipping costs on purchases and shipping and handling fees related to sales charged to customers are both included in cost of sales. As mentioned in Revenue Recognition, shipping and handling revenue billed customers are reflected in other revenues.
Concentration of Credit Risk	'
	Concentration of Credit Risk
	Financial instruments that potentially subject the Company to concentration of credit risk consist principally of trade accounts receivables. Concentrations of credit with respect to trade receivables are limited due to the large number of customers comprising the Company’s customer bases and their dispersion across different geographic locations.
	The Company maintains cash balances at one financial institution located in Colorado and one in California. Accounts at these institutions are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000 per account. At times during the year, the Company’s bank balances have exceeded the FDIC limit. Management believes the risk of loss at such institutions to be minimal.
Use of Estimates	'
	Use of Estimates
	The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include but are not limited to the fair value determination of derivative instruments, the valuation allowance with respect to estimated utilization of net operating losses, estimated allowances for sales returns and collectability of trade receivables.
Earnings (Loss) Per Share	'
	Earnings (Loss) Per Share
	Net earnings (loss) per share is computed by dividing net income (loss) less preferred dividends for the period by the weighted average number of shares of common stock outstanding during each period. Diluted earnings (loss) per share is computed by dividing net income (loss) less preferred dividends for the period by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during each period.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Estimated Fair Value of Financial Instruments	'
		30-Jun-14					31-Dec-13
		Carrying		Fair Value			Carrying		Fair Value
		Amount					Amount
	Cash and cash equivalents	$	1,717,916	$	1,717,916		$	822,876	$	822,876
	Receivables	$	2,148,148	$	2,148,148		$	2,398,178	$	2,398,178
	Accounts Payable	$	1,354,883	$	1,354,883		$	1,248,490	$	1,248,490
	Derivative Liability	$	279,013	$	279,013		$	471,015	$	471,015
Trade Receivables and Credit Policy	'
		June 30,		December 31,
		2014		2013
	Trade Receivables	$	2,085,330	$	2,323,522
	Other	$	62,817	$	74,656
	Allowance for doubtful accounts	$	0	$	0
	Totals	$	2,148,147	$	2,398,178
Inventory Valuation	'
		June 30,		December 31,
		2014		2013
	Labels and packaging	$	182,397	$	120,057
	Raw materials	$	79,836	$	207,320
	Finished goods	$	1,984,571	$	1,658,387
	Totals	$	2,246,804	$	1,985,764
Earnings (Loss) Per Share	'
			Three Months Ended			Six Months Ended
			2014	2013		2014		2013
	Basic weighted average common shares outstanding		12,866,401	12,686,928		12,883,026		12,645,842
	Stock options (exercise price – $0.573-$2.50/share)		382,258	614,488		413,280		581,145
	Warrants (exercise price – $0.001-$2.25/share)		418,095	437,450		418,491		431,648
	Total common stock equivalents		13,686,754	13,738,866		13,714,797		13,658,635

Fair_Value_Measurements_and_Di1

Fair Value Measurements and Disclosures (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis	'
		30-Jun-14						31-Dec-13
		Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
	Balance	$	35,185	$	0	$	279,013	$	108,228	$	0	$	471,015
	Beginning of Period		108,228		-		471,015		29,338		-		701,852
	Deletions		-87,843		-		-		-36,103		-		-87,755
	Revisions		14,800		-		-192,002		114,993		-		-143,082
	End of Period	$	35,185	$	0	$	279,013	$	108,228	$	0	$	471,015

Summary_of_Significant_Account2

Summary of Significant Accounting Policies - Fair Value Measurements (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2012
Fair Value of Assets and Liabilities	'	'	'	'
Cash and cash equivalents, carrying value	$1,717,916	$822,876	$2,402,908	$1,655,453
Receivables, carrying value	2,148,148	2,398,178	'	'
Accounts Payable, carrying value	1,354,883	1,248,490	'	'
Derivative Liability, carrying value	279,013	471,015	'	'
Cash and cash equivalents, fair value	1,717,916	822,876	'	'
Receivables, fair value	2,148,148	2,398,178	'	'
Accounts Payable, fair value	1,354,883	1,248,490	'	'
Derivative Liability, fair value	$279,013	$471,015	'	'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Trade Receivables and Credit Policy (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Trade Receivables	'	'
Trade Receivables	$2,085,330	$2,323,522
Other	62,817	74,656
Allowance for doubtful accounts	0	0
Total trade receivables, net	$2,148,148	$2,398,178

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Inventory Valuation (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Inventory Valuation	'	'
Labels and packaging	$182,397	$120,057
Raw materials	79,836	207,320
Finished goods	1,984,571	1,658,387
Total inventories	$2,246,804	$1,985,764

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Earnings (Loss) Per Share (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Basic weighted average common shares outstanding	12,886,401	12,686,928	12,883,026	12,654,842
Total common stock equivalents	13,686,754	13,738,866	13,714,797	13,658,635
Stock Options - Exercise Price $0.573-$2.50/Share	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from earnings per share calculation	382,258	614,488	413,280	581,145
Warrants - Exercise Price $0.001-$2.25/Share	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from earnings per share calculation	418,095	437,450	418,491	431,648

Summary_of_Significant_Account6

Summary of Significant Accounting Policies - Concentration of Credit Risk (Details Narrative)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Customer Concentration Risk - Revenue	'	'
Concentration Risk [Line Items]	'	'
Concentration risk, percentage	66.00%	57.00%
Customer Concentration Risk - Accounts Receivable	'	'
Concentration Risk [Line Items]	'	'
Concentration risk, percentage	80.00%	56.00%
Vendor Concentration Risk - Purchases	'	'
Concentration Risk [Line Items]	'	'
Concentration risk, percentage	63.00%	78.00%
Vendor Concentration Risk - Accounts Payable	'	'
Concentration Risk [Line Items]	'	'
Concentration risk, percentage	48.00%	68.00%

Summary_of_Significant_Account7

Summary of Significant Accounting Policies (Details Narrative) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Sales Returns and Allowances	'	'	'	'	'
Allowance for customer returns	'	'	$85,000	'	$70,000
Receivables	'	'	'	'	'
Note receivable	89,071	'	89,071	'	'
Note receivable, additional disclosure	'	'	'	'	'The predecessor company disposed of a dormant product line of vitamins in December 2010. As part of the consideration in this divestiture, the Company received from the purchaser of this product line an unsecured note in the amount of $170,000. The original note was due to be repaid on or before March 2014, where interest accrued principally at an annual rate of 5%, based upon the initial $170,000 principal and was payable monthly. As of March 31, 2013, the note was novated and a new promissory note was issued to reflect a modification in the payment terms, which includes no interest.
Note receivable, maturity date	'	'	1-May-17	'	'
Revenue Recognition	'	'	'	'	'
Revenue recognition, returns, allowances and discounts	849,356	293,498	1,360,091	1,008,528	'
Deferred revenue	214,977	'	214,977	'	292,215
Leases	'	'	'	'	'
Leases, rent expense	20,716	20,716	41,432	41,432	'
Leases, description	'	'	'The Company leases its headquarters facility, comprising approximately 10,044 square feet, in Golden, Colorado. The lease term expires January 31, 2017 and requires equal monthly payments over the remaining term.	'	'
Leases, future payments	214,063	'	214,063	'	'
Marketing	'	'	'	'	'
Marketing, deferred advertising costs	0	'	0	'	7,651
Marketing, expense	314,696	178,720	942,119	324,930	'
Research and Development Expense	'	'	'	'	'
Research and development costs	$4,481	$28,701	$10,905	$88,514	'

Income_Taxes_Details_Narrative

Income Taxes (Details Narrative) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Tax Disclosure [Abstract]	'	'	'	'
Income tax expense (benefit)	($63,382)	$194,348	($79,205)	$184,214

Stockholders_Equity_Details_Na

Stockholders' Equity (Details Narrative) (USD $)	3 Months Ended	6 Months Ended		3 Months Ended		6 Months Ended	3 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014
				Warrant Grants - Breakwater Structured Growth Opportunity Fund	Warrant Grants - Breakwater Structured Growth Opportunity Fund	Warrant Grants - Breakwater Structured Growth Opportunity Fund	Business Development Consultant	Business Development Consultant	Option Grant #1 - Company Employee	Option Grant #2 - Company Employee
Class of Stock [Line Items]	'	'	'	'	'	'	'	'	'	'
Common stock issued for services	'	'	'	'	'	'	'	7,500	'	'
Stock options issued	'	'	'	'	'	'	'	'	10,000	6,000
Stock options, outstanding	12,887,151	12,887,151	12,879,651	'	'	'	'	'	'	'
Common stock, par value in dollars	$0.01	$0.01	$0.01	'	'	'	$0.01	$0.01	'	'
Stock options exercise price	'	'	'	'	'	'	'	'	$2.50	$2.22
Stock warrants granted	'	'	'	'	'	420,549	'	'	'	'
Stock warrant, rights	'	'	'	'	'	'The company issued warrants to purchase 3% of fully diluted shares of the common stock of the Company to Breakwater Structured Growth Opportunity Fund, L.P., with an imputed exercise price equal to approximately one-hundredth of a dollar in connection with a $1.025 million subordinated mezzanine loan arrangements.	'	'	'	'
Stock options and warrants granted expiration date	'	'	'	'	'	15-Jun-16	'	'	15-Oct-23	10-Feb-24
Stock options and warrants vesting period	'	'	'	'	'	'Fully vested	'	'	'Three year vesting schedules of 1/3 each year through October 2016.	'Three year vesting schedules of 1/3 each year through February 2017.
Stock value, lattice model method	'	'	'	'	'	'The Company used a lattice model in developing a fair value for the Breakwater warrant obligation at June 30, 2014, using a quoted stock value of $0.68 per share, which represents a discount of 50% from the closing stock price. This reduction was based on the application of a discount for lack of liquidity.	'	'	'	'
Discount assumption	'	'	'	'	'	50.00%	'	'	50.00%	50.00%
Risk free interest rate	'	'	'	'	'	0.47%	'	'	'	'
Risk free interest rate, minimum	'	'	'	'	'	'	'	'	2.13%	2.13%
Risk free interest rate, maximum	'	'	'	'	'	'	'	'	2.41%	2.41%
Stock price	'	'	'	$0.68	'	$0.68	$2.17	$2.17	'	'
Stock price, lower range	'	'	'	'	'	'	'	'	$1.11	$1.11
Stock price, upper range	'	'	'	'	'	'	'	'	$1.25	$1.25
Stock price, range	'	'	'	'	'	'1.05437284 to 0.94843111	'	'	'	'
Risk neutral probabilities, range	'	'	'	'	'	'0.4876197 to 0.5123803	'	'	'	'
Weighted average expected term	'	'	'	'	'	'2 years 1 month	'	'	'	'
Weighted average expected term, minimum	'	'	'	'	'	'	'	'	'6 years 1 month	'6 years 1 month
Weighted average expected term, maximum	'	'	'	'	'	'	'	'	'6 years 4 months	'6 years 4 months
Weighted average expected volatility	'	'	'	'	'	38.18%	'	'	35.22%	35.22%
Allocated share-based compensation expense	$6,017	$12,122	'	'	'	'	$16,275	$16,275	'	'
Other operating income	'	'	'	191,279	58,837	192,002	'	'	'	'
Other operating expense	'	'	'	'	'	$100,968	'	'	'	'

Revolving_Line_of_Credit_and_R1

Revolving Line of Credit and Related Interest (Details Narrative) (USD $)	1 Months Ended
	Jul. 31, 2012	Jun. 30, 2014	Dec. 31, 2013	Jul. 16, 2012
Line Of Credit Facility	'	'	'	'
Line of Credit	'	'	'	$1,500,000
Line of Credit, maturity date	16-Nov-14	'	'	'
Line of Credit, interest rate description	'The principal balance will note bear interest at the one month USD LIBOR rate measured not more often than once per month (the "Index"). Interest on any unpaid balance will bear interest at the Index plus 3.750% with a minimum interest rate of 4.00% per annum..	'	'	'
Line of Credit, balance outstanding	'	$1,220,519	$1,220,655	'

Fair_Value_Measurements_and_Di2

Fair Value Measurements and Disclosures (Details) (Derivative Financial Instruments, USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Fair Value Inputs - Level 1	'	'
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Marketable Securities and Warrant derivative liability at beginning of year	$108,228	$29,338
Marketable Securities and Warrant derivative liability, deletions	-87,843	-36,103
Marketable Securities and Warrant derivative liability, revisions	14,800	114,993
Marketable Securities and Warrant derivative liability at end of year	35,185	108,228
Fair Value Inputs - Level 3	'	'
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Marketable Securities and Warrant derivative liability at beginning of year	471,015	701,852
Marketable Securities and Warrant derivative liability, deletions	0	-87,755
Marketable Securities and Warrant derivative liability, revisions	-192,002	-143,082
Marketable Securities and Warrant derivative liability at end of year	$279,013	$471,015

Fair_Value_Measurements_and_Di3

Fair Value Measurements and Disclosures (Details Narrative) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'	'
Assets held for sale	$35,185	$108,228